Working… Menu

A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01313143
Recruitment Status : Completed
First Posted : March 11, 2011
Last Update Posted : July 19, 2012
Information provided by (Responsible Party):
AOP Orphan Pharmaceuticals AG

Brief Summary:
Pharmacokinetics, pharmacodynamics and tolerability of AOP200704 infusion is compared to that of Esmolol by measurement of plasma concentrations of AOP200704, esmolol and their metabolites, by assessing the effect of both drugs on dobutamine-induced tachycardia, and by monitoring vital signs, ECG and adverse events.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Pharmacokinetics/Dynamics Study Drug: AOP200704 Drug: Esmolol hydrochloride, infusion Phase 2

Detailed Description:
16 healthy volunteers of both sexes, age 18 to 45 years, will be enrolled. The mean dose necessary to suppress the Dobutamine induced heart rate increase of at least 30 bpm above baseline rate (maximum heart rate app. 110 bpm) by at least 20 bpm will be calculated for AOP200704 and Esmolol and the dose/efficacy relation of both agents to each other will be calculated for the steady state condition. For both drugs the time to reach a decrease of 10 bpm, 20 bpm and the maximum effect will be calculated. In addition the mean time to increase in 10 and 20 bpm and the time to reach maximum heart rate (increase of 30 bpm above baseline or more) after termination of infusion will also be assessed for both drugs. Blood pressure values will be compared for all above mentioned time points where heart rate is assessed for pharmacodynamics.The study will consist of a screening, cross-over 1, cross-over 2 and end-of-study visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Prospective, Randomized, Double Blinded, Crossover, Two-treatment, Two-sequence, Short Term Pharmacokinetic, Pharmacodynamic and Tolerability, Single Centre Study to Compare AOP200704 vs. Esmolol in Healthy Subjects.
Study Start Date : March 2011
Actual Primary Completion Date : May 2011
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: AOP200704, infusion Drug: AOP200704
Comparison of AOP200704 with Esmolol

Active Comparator: Esmolol, infusion Drug: Esmolol hydrochloride, infusion
Comparison of AOP200704 with Esmolol

Primary Outcome Measures :
  1. Pharmacokinetics/dynamics [ Time Frame: 9 hours ]

Secondary Outcome Measures :
  1. Local tolerability [ Time Frame: 9 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Male and female human subjects, age 18-45 years
  • Body weight of at least 50 kg, maximum of 90 kg. Body-mass index 18.5 to 30.0 kg/m2
  • Caucasians
  • Subjects without clinically relevant abnormalities
  • Subjects agreeing to not using any prescription and over the counter medications including vitamins and minerals for 7 days prior to study and during the course of the study
  • No drug or alcohol abuse
  • Non-smokers, ex smokers and mild smokers

Exclusion Criteria:

  • Subjects with history or presence of clinically relevant cardiovascular, renal, hepatic, ophthalmic, pulmonary, neurological, metabolic, hematological, gastrointestinal, endocrine, immunological, psychiatric or skin diseases.
  • Subjects with bradycardia (heart rate below 50 bpm), tachycardia (heart rate above 100 bpm), hypotension (systolic blood pressure below 100 mmHg, and/or diastolic blood pressure below 70 mm Hg) at screening, clinically relevant or history of clinically relevant arrhythmias
  • Subjects with clinically relevant cardiac supraventricular or ventricular arrhythmias.
  • Subjects with atrioventricular block of grade II and III, sick sinus syndrome, sinoatrial block or congestive heart failure
  • Participation in a clinical drug study or bioequivalence study 60 days prior to present study.
  • History of malignancy or other serious diseases.
  • Any contraindication to blood sampling.
  • History of i.v. drug abuse.
  • Subjects with positive HIV tests, HBsAg or Hepatitis C tests or other acute, subacute or chronic infectious disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01313143

Layout table for location information
Czech Republic
AOP contract research facility
Pilsen, Czech Republic, 32300
Sponsors and Collaborators
AOP Orphan Pharmaceuticals AG
Layout table for investigator information
Principal Investigator: AOP Study Principal Investigator AOP Contract Clinical Research Facility
Layout table for additonal information
Responsible Party: AOP Orphan Pharmaceuticals AG Identifier: NCT01313143    
Other Study ID Numbers: CPA368-10
First Posted: March 11, 2011    Key Record Dates
Last Update Posted: July 19, 2012
Last Verified: July 2012
Keywords provided by AOP Orphan Pharmaceuticals AG:
AOP200704, Esmolol, Pharmacokinetics, Pharmacodynamics
Additional relevant MeSH terms:
Layout table for MeSH terms
Adrenergic beta-1 Receptor Antagonists
Adrenergic beta-Antagonists
Adrenergic Antagonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs